trending Market Intelligence /marketintelligence/en/news-insights/trending/afC9EAuv-80uFEVrvhr7lw2 content esgSubNav
In This List

AstraZeneca's lung cancer treatment Imfinzi granted priority review by FDA

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


AstraZeneca's lung cancer treatment Imfinzi granted priority review by FDA

AstraZeneca PLC and MedImmune's Imfinzi was granted priority review status by the U.S. Food and Drug Administration as it accepted a supplemental biologics license application, or sBLA, for the lung cancer treatment.

The sBLA is based on positive data from the phase 3 Pacific trial of Imfinzi. The study is continuing to evaluate overall survival under the treatment, the trial's other primary endpoint.

Imfinzi or durvalumab, is a monoclonal antibody indicated for treating patients with locally advanced, or Stage 3, unresectable non-small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy.

Imfinzi was granted breakthrough therapy designation by the U.S. FDA in July.

MedImmune is AstraZeneca's biologics research and development unit.